DigestRedComo funciona
Red
/
Empresas
Ge
No verificado

Genentech

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

87 Comunicados de prensa

Ver todos los comunicados de prensa
11/06/2026
Industria
Oncología
Higiene alimentaria
Salud
Medicina - Varios
Farmacéutica
Biotecnología
FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer
Fuente
Genentech
Editor
Business Wire
1.00
0
02/06/2026
Oncología
Higiene alimentaria
Salud
Medicina - Varios
Farmacéutica
Biotecnología
FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting
Fuente
Genentech
Editor
Business Wire
1.00
0
01/06/2026
Eventos
Web y redes sociales
Salud
Medicina - Varios
Sanidad
Farmacéutica
Biotecnología
Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Fuente
Genentech
Editor
Business Wire
1.00
0
19/05/2026
Eventos
Ferias y Congresos
Industria
Biotecnología
Farmacéutica
Salud
Oncología
Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer
Fuente
Genentech
Editor
Business Wire
1.00
0
15/05/2026
Industria
Biología
Biotecnología
Higiene alimentaria
Salud
Farmacéutica
Oncología
Ciencia
Medicina - Varios
FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
Fuente
Genentech
Editor
Business Wire
1.00
0
30/04/2026
Eventos
Ferias y Congresos
Industria
Ciencia
Biotecnología
Farmacéutica
Óptica
Sanidad
Salud
Medicina - Varios
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026
Fuente
Genentech
Editor
Business Wire
1.00
0
24/04/2026
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign
Fuente
Genentech
Editor
Business Wire
1.00
0
21/04/2026
Eventos
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
Fuente
Genentech
Editor
Business Wire
1.00
0
21/04/2026
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD
Fuente
Genentech
Editor
Business Wire
1.00
0
21/04/2026
Eventos
Ferias y Congresos
Industria
Salud
Higiene alimentaria
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
CORRECTING and REPLACING FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus
Fuente
Genentech
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0